Skip to content
10-Q

Quarterly Report

BIOCRYST PHARMACEUTICALS INC BCRX

0001628280-25-037795

← back to feed
Filed
Aug 5, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2025 · Jul 31, 2025 209.92M sh
Shares Diluted Q2 2025 · Jun 30, 2025 219.89M sh
Shares Diluted Q2 2025 · Jun 30, 2025 217.57M sh
Shares Diluted Q2 2025 · Jun 30, 2024 206.43M sh
Shares Diluted Q2 2025 · Jun 30, 2024 206.24M sh
Operating Cash Flow Q2 2025 · Jun 30, 2025 $13.79M
Operating Cash Flow Q2 2025 · Jun 30, 2024 −$55.05M
Long Term Debt Q2 2025 · Jun 30, 2025 $242.79M
Long Term Debt Q2 2025 · Dec 31, 2024 $314.87M
Short Term Investments Q2 2025 · Jun 30, 2025 $172.01M
Short Term Investments Q2 2025 · Dec 31, 2024 $216.14M
Cash And Equivalents Q2 2025 · Jun 30, 2025 $88.03M
Cash And Equivalents Q2 2025 · Dec 31, 2024 $104.71M
Cash And Equivalents Q2 2025 · Jun 30, 2024 $78.41M
Stockholders Equity Q2 2025 · Jun 30, 2025 −$421.59M
Stockholders Equity Q2 2025 · Mar 31, 2025 −$451.93M
Stockholders Equity Q2 2025 · Dec 31, 2024 −$475.93M
Stockholders Equity Q2 2025 · Jun 30, 2024 −$475.61M
Stockholders Equity Q2 2025 · Mar 31, 2024 −$476.17M
Stockholders Equity Q2 2025 · Dec 31, 2023 −$455.53M
Current Liabilities Q2 2025 · Jun 30, 2025 $177.16M
Current Liabilities Q2 2025 · Dec 31, 2024 $160.38M
Total Liabilities Q2 2025 · Jun 30, 2025 $878.78M
Total Liabilities Q2 2025 · Dec 31, 2024 $966.35M
Current Assets Q2 2025 · Jun 30, 2025 $398.46M
Current Assets Q2 2025 · Dec 31, 2024 $421.97M
Total Assets Q2 2025 · Jun 30, 2025 $457.19M
Total Assets Q2 2025 · Dec 31, 2024 $490.42M
Eps Diluted Q2 2025 · Jun 30, 2025 $0.02
Eps Diluted Q2 2025 · Jun 30, 2025 $0.02
Eps Diluted Q2 2025 · Jun 30, 2024 −$0.06
Eps Diluted Q2 2025 · Jun 30, 2024 −$0.23
Eps Basic Q2 2025 · Jun 30, 2025 $0.02
Eps Basic Q2 2025 · Jun 30, 2025 $0.02
Eps Basic Q2 2025 · Jun 30, 2024 −$0.06
Eps Basic Q2 2025 · Jun 30, 2024 −$0.23
Sga Expense Q2 2025 · Jun 30, 2025 $87.38M
Sga Expense Q2 2025 · Jun 30, 2025 $169.85M
Sga Expense restated Q2 2025 · Jun 30, 2024 $61.25M
Sga Expense restated Q2 2025 · Jun 30, 2024 $120.74M
Rd Expense Q2 2025 · Jun 30, 2025 $43.39M
Rd Expense Q2 2025 · Jun 30, 2025 $80.66M
Rd Expense Q2 2025 · Jun 30, 2024 $37.62M
Rd Expense Q2 2025 · Jun 30, 2024 $84.12M
Net Income Q2 2025 · Jun 30, 2025 $5.09M
Net Income Q2 2025 · Jun 30, 2025 $5.12M
Net Income Q2 2025 · Mar 31, 2025 $32K
Net Income Q2 2025 · Jun 30, 2024 −$12.67M
Net Income Q2 2025 · Jun 30, 2024 −$48.05M
Net Income Q2 2025 · Mar 31, 2024 −$35.38M
Operating Income Q2 2025 · Jun 30, 2025 $29.79M
Operating Income Q2 2025 · Jun 30, 2025 $51.01M
Operating Income Q2 2025 · Jun 30, 2024 $8.76M
Operating Income Q2 2025 · Jun 30, 2024 −$5.73M
Cost Of Revenue Q2 2025 · Jun 30, 2025 $2.8M
Cost Of Revenue Q2 2025 · Jun 30, 2025 $7.37M
Cost Of Revenue Q2 2025 · Jun 30, 2024 $1.7M
Cost Of Revenue Q2 2025 · Jun 30, 2024 $2.96M